tm logo
AMCLERUS
FORMALIZED

on 03 Apr 2024

Last Applicant/ Owned by

PROTHENA BIOSCIENCES LIMITED

77 Sir John Rogerson's Quay,Block C, Grand Canal Docklands,Dublin 2D02 T804

IE

Serial Number

2319616 filed on 02th Feb 2024

AMCLERUS

Trademark usage description

biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, onco Read More

Classification Information


Class [005]
Biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of autoimmune, metastatic, hematologic, oncologic, ocular and neurologic diseases, conditions and disorders; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders associated with misfolded proteins; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of diseases, conditions and disorders affecting the central nervous system; biopharmaceuticals and pharmaceuticals for the prevention, treatment, management, diagnosis and prognosis of amyloidosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, dermatitis, host and graft rejections, Alzheimer's and Parkinson's-disease associated neuropsychiatric disorders, insulin resistance, metabolic syndrome and diabetes.


Classification kind code

12

Class [042]
Research and development in the pharmaceutical and biotechnology fields.


Classification kind code

12

Class [045]
Licensing of intellectual property in the field of biotechnology.


Classification kind code

12

Mark Details


Serial Number

2319616

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 257
on 04th Apr 2024
Designation Notification - Madrid Protocol
Submitted for opposition 1
on 03rd Apr 2024
Created
Submitted for opposition 31
on 03rd Apr 2024
Formalized
Submitted for opposition 228
on 02th Feb 2024
International Registration
Submitted for opposition 30
on 02th Feb 2024
Filed